about the author

Kyle Blankenship

kyle@endpointsnews.com @ka_blankenship
Kyle Blankenship on LinkedIn

author articles

Mer­ck gets a PDU­FA date for its chron­ic cough con­tender; Mor­phic shares sky­rock­et on the heels of PhI da­ta roll­out in ...

5 years ago
News Briefing

Mer­ck KGaA ear­marks $855M for De­bio­phar­m's pro­grammed cell death pro­mot­ing drug in glob­al li­cens­ing deal

5 years ago
Deals
R&D

Am­gen, As­traZeneca speed to­ward fil­ing next-gen an­ti­body for asth­ma af­ter un­cork­ing full late-stage da­ta

5 years ago
R&D

Biden wants a re­view of the API sup­ply chain. Will that par­lay in­to an ef­fort to 'on­shore' drug man­u­fac­tur­ing?

5 years ago
Outsourcing
Manufacturing

Mer­ck takes a swing at the IL-2 puz­zle­box with a $1.85B play for buzzy Pan­dion and its au­toim­mune hope­fuls

5 years ago
Deals
Pharma

Glax­o­SmithK­line re­thinks strat­e­gy for Covid-19 an­ti­body — not the Vir ones — af­ter tri­al flop. Is there hope in ...

5 years ago
R&D
Coronavirus

Japan's Soft­Bank plots bil­lions in biotech in­vest­ments in move that could keep the val­u­a­tion flood ris­ing — re­port

5 years ago
People
Financing

Bris­tol My­ers scales up cell ther­a­py pro­duc­tion with liso-cel nod in hand and an­oth­er ap­proval maybe on the way

5 years ago
Cell/Gene Tx
Manufacturing

Catal­ent un­corks play in plas­mid DNA with buy­out of Bel­gian neigh­bor Del­phi, Mary­land ex­pan­sion launch

5 years ago
Outsourcing
Manufacturing

Bio­phar­ma's suc­cess rate in bring­ing drugs to mar­ket has long been abysmal. Can new tools help rewrite that trou­bled ...

5 years ago
In Focus

Eli Lil­ly's David Ricks snared $24M pay pack­age in a year tur­bo-boost­ed by Covid-19 an­ti­body

5 years ago
People

In­cyte scores speedy FDA re­view for JAK cream in atopic der­mati­tis; Lil­ly backs $90M raise for Re­gor

5 years ago
News Briefing

Ab­b­Vie puts an end to Botox trade se­crets suit, im­pos­es roy­al­ty, li­cense deal on com­peti­tor Evo­lus

5 years ago
Pharma

Astel­las scores a pair of tri­al wins for menopausal hot flash med, rais­ing the pitch of loom­ing Bay­er stand­off

5 years ago
R&D

Mallinck­rodt be­comes the lat­est vic­tim of the FDA's pan­dem­ic-re­lat­ed de­lays as it push­es off ap­pli­ca­tion for skin ...

5 years ago
Pharma
FDA+

Is­raeli API mak­er Wave­length buys up ma­jor­i­ty stake in In­di­an firm mak­ing drug start­ing ma­te­ri­als and in­ter­me­di­ates

5 years ago
Outsourcing
Manufacturing

Eli Lil­ly adds new board mem­ber Kim­ber­ly John­son, the COO who helped lead Fan­nie Mae out of the US hous­ing cri­sis

5 years ago
People
Pharma

Weeks af­ter drop­ping big re­sponse da­ta, Am­gen lines up pri­or­i­ty re­view for KRAS hope­ful so­tora­sib in NSCLC

5 years ago
Pharma
FDA+

No­var­tis' En­tresto, fac­ing a big come­back in hard-to-treat heart fail­ure pa­tients, scores FDA nod af­ter ad­comm ...

5 years ago
Pharma
FDA+

Cel­lec­tis signs $760M mile­stone deal with NK up­start; Im­muno­core brings on As­traZeneca vet to shep­herd bis­pe­cif­ic ...

5 years ago
News Briefing

As­traZeneca's Pas­cal So­ri­ot picks up $21.5M pay pack­age in 2020, a big haul in year marked by Covid-19 shot ...

5 years ago
People

An­oth­er Keytru­da com­bo tops stan­dard of care in ad­vanced kid­ney can­cer, pos­ing new test for Bris­tol's I/O med

5 years ago
Pharma

Astel­las, Seagen pave the way for Pad­cev's glob­al roll­out with full con­fir­ma­to­ry da­ta for urothe­lial can­cer in hand

5 years ago
Pharma
FDA+

Gy­ro­scope posts ear­ly win with gene ther­a­py for AMD, giv­ing hope for its im­mune com­ple­ment sys­tem tar­get

5 years ago
R&D
First page Previous page 15161718192021 Next page Last page
A service from the Financial Times